Literature DB >> 7494001

Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor.

Y Shishido1, K D Sharma, S Higashiyama, M Klagsbrun, E Mekada.   

Abstract

Diphtheria toxin receptor (DTR), which is identical to the membrane-anchored form of heparin-binding EGF-like growth factor (proHB-EGF), has a high affinity for heparin. We studied the effect of heparin-like molecules on the binding of diphtheria toxin (DT) to DTR/proHB-EGF. Mutant Chinese hamster ovary (CHO) cells deficient in heparan sulfate (HS) proteoglycans were about 15 times less sensitive to DT than wild type CHO-K1 cells. When free heparan sulfate or heparin was added to the culture medium, DT sensitivity of the mutant cells was fully restored. Studies of binding of 125I-labeled DT to HS-deficient CHO cells transfected with human DTR/proHB-EGF cDNA indicated that the increased sensitivity to DT after addition of heparin is due to increased binding of DT to cells. Vero cells display a relatively large amount of heparan sulfate residues compared to CHO-K1 cells or L cells. Enhancement of DT binding by the addition of heparin was also observed with CHO-K1 cells and L cells that had been transfected with human DTR/proHB-EGF cDNA, but the degree of enhancement was less than that observed with the HS-deficient CHO cells. Addition of heparin did not affect DT binding or DT sensitivity of Vero cells. Heparin-dependent binding was observed when intact Vero cells were treated with heparitinase or when the cell membrane was solubilized with a neutral detergent. Scatchard plot analysis for the binding of DT to a recombinant HB-EGF in vitro and to L cells expressing human DTR/proHB-EGF revealed that heparin increases the affinity of DTR/proHB-EGF for DT but does not change the number of binding sites. Although DRAP27/CD9 is known to enhance DT binding to DTR/proHB-EGF, the results indicate that heparin and DRAP27/CD9 increase DT binding by independent mechanisms. Thus, heparin-like molecules, probably in the form of heparan sulfate proteoglycan on the cell surface, are a third factor required for maximal DT binding activity of cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494001     DOI: 10.1074/jbc.270.49.29578

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration.

Authors:  E Nishi; A Prat; V Hospital; K Elenius; M Klagsbrun
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

2.  Tumor attenuation by combined heparan sulfate and polyamine depletion.

Authors:  Mattias Belting; Lubor Borsig; Mark M Fuster; Jillian R Brown; Lo Persson; Lars-Ake Fransson; Jeffrey D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

3.  Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder.

Authors:  M R Freeman; J J Yoo; G Raab; S Soker; R M Adam; F X Schneck; A A Renshaw; M Klagsbrun; A Atala
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  Heparin-binding epidermal growth factor-like growth factor is a potent neurotrophic factor for PC12 cells.

Authors:  Yu Zhou; Gail E Besner
Journal:  Neurosignals       Date:  2010-09-16

Review 5.  Syndecans: multifunctional cell-surface co-receptors.

Authors:  D J Carey
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

6.  Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.

Authors:  Angela L Gaviglio; Erik H Knelson; Gerard C Blobe
Journal:  FASEB J       Date:  2017-02-07       Impact factor: 5.191

7.  Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling.

Authors:  Xiaochun Yu; Kailash D Sharma; Tsuyoshi Takahashi; Ryo Iwamoto; Eisuke Mekada
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

8.  Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.

Authors:  Jixin Yang; Yanwei Su; Yu Zhou; Gail E Besner
Journal:  Pathophysiology       Date:  2013-12-15

9.  Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate.

Authors:  Ryan J Weiss; Philipp N Spahn; Austin W T Chiang; Qing Liu; Jing Li; Kristina M Hamill; Sandra Rother; Thomas M Clausen; Marten A Hoeksema; Bryce M Timm; Kamil Godula; Christopher K Glass; Yitzhak Tor; Philip L S M Gordts; Nathan E Lewis; Jeffrey D Esko
Journal:  Nat Chem Biol       Date:  2021-04-12       Impact factor: 15.040

10.  Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody.

Authors:  Shuji Sato; Hiroko Kamada; Takahiro Watanabe; Isamu Tsuji; Jinhong Fan
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.